Figure 1
From: Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial
Study design. Children aged 12 to 18 years with peanut allergy proven in a first double-blind placebo-controlled oral food challenge (DBPCOFC) will enter a double-blind placebo-controlled induction phase through a first 2:1 randomization (R1). After a successful build-up phase, the maintenance phase duration will be determined by a second 1:1 randomization (R2). Double arrow: DBPCOFC. (dotted area: 24 weeks normal dietary; shaded area : 6 weeks wash-out).